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oo.com (Abstract Background: More than 85% of patients with primary hyperparathyroidism (PHPT)
have a single adenoma. This fact when combined with the recent advances in preoperative imaging
diagnostic modalities and intraoperative identiﬁcation of the diseased gland has allowed the devel-
opment of minimally invasive endoscopic assisted parathyroidectomy (MIEAP).
Objective: Treatment of patients with primary hyperparathyroidism due to a single gland dis-
ease, with minimally invasive endoscopic-assisted parathyroidectomy.
Subjects and methods: Nine patients (seven females and two males) with PHPT were proved to
have a single-gland parathyroid adenoma after preoperative imaging techniques. They were sched-
uled for MIEAP, with intraoperative identiﬁcation by MB.
Results: Surgical time ranged between 21 and 35 min through a small surgical wound and cure
rate of 100% with no recorded complications.Ear, Nose, Throat and Allied
evier B.V. All rights reserved.
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Table 1 Patients’ characteristics
adenoma. Also, the maximum size o
inferior; Li: left inferior; RS: right s
No. Sex Age
1 F 44
2 F 42
3 F 42
4 F 50
5 M 43
6 F 53
7 M 51
8 F 43
9 F 44
N.B.; (+ve) test done with positive de
26 M.H. Thabet et al.Conclusion: MIEAP is an easy, safe and effective maneuver for management of PHPT due to a
localized adenoma. It is less costly with a cosmetically-accepted wound.
ª 2012 Egyptian Society of Ear, Nose, Throat and Allied Sciences.
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Bilateral neck exploration was the standard operation for pri-
mary hyperparathyroidism (PHPT). The goal of the procedure
was to identify all four parathyroid glands and to remove all
abnormal parathyroid tissues.1,2 A 70% cure rate was re-
ported, but this approach was accomplished via a large inci-
sion with all its related morbidities and difﬁcult second
surgeries.3 More than 80% of parathyroid adenomas can be
localized preoperatively.1,4 This idea together with the
improvement in imaging techniques has made the application
of minimal-access approaches to primary parathyroid disease
a reality, also the combination of more than one imaging tech-
nique offers 95–98% accuracy.5–7 There are many reports of
minimal incision parathyroidectomy with the intraoperative
identiﬁcation of the affected gland, with subsequent better
and precise management of patients with less morbidity, less
cost and much better cosmetic appearance than with ordinary
wide approach.8–10
Methylene blue (MB) has been used intraoperatively since
1971 to aid in gland identiﬁcation11 as it selectively stains para-
thyroid tissues, thus facilitating surgery. The dye stains adeno-
mas and hyperplastic glands a deep purple-blue color, while
normal parathyroid tissue stains to a lesser extent or not at
all.12 Up until recently, it has been considered a safe and
cost-effective modality to use, whether by itself13,14 or as a com-
plement to other preoperative imaging identiﬁcation tools.8
The aim of this work is to present the way for a minimally
invasive, endoscopic-assisted parathyroidectomy (MIEAP)
paved by preoperative imaging localization and intraoperative
methylene blue (MB) identiﬁcation.
2. Patients and methods
Nine patients with primary hyperparathyroidism (PHPT) due
to single-gland parathyroid adenoma were treated by MIEAP.
They were managed at Fakhry and AlRajhi Hospitals, AlKho-with various preoperative and
f excised mass (in mm) and oper
uperior; LS: left superior; MB: m
Site Max. size (mm)
LS 22
RI 14
RI 20
LS 12
RS 23
Li 16
RI 18
RI 13
LS 20
tection, (ve) test done with negabar, KSA, in the period between June 2005 and November
2010. The patients’ characteristics are summarized in Table
1. There were seven females and two males, with an age range
from 42 to 53 years. Patients were evaluated by thorough his-
tory taking, clinical assessment and laboratory tests.
Ultrasonography (US), CT, MRI and Technetium (Tc)-99m
(sestamibi) scans were performed for 9, 6, 4 and 4 patients,
respectively. Sestamibi scans were performed using the single
agent wash-out technique and images were obtained at 10
and 90 min after isotope administration. Patients were scanned
using a gamma camera. Parathyroid adenomas were localized
preoperatively in all nine patients. Exclusion criteria for pa-
tient selection were: (1) non-localized adenomas, (2) previous
neck surgery, (3) large goiters, (4) multiple endocrine neopla-
sia, (5) over weight, and (6) familial hypocalciuric hypercalce-
mia. Patients on drugs like acetylsalicylic acid, ibuprofen,
high-dose vitamin E were instructed to stop medications
10 days before surgery to avoid perioperative bleeding. Pa-
tients taking antidepressant drugs were asked to stop medica-
tion 4 weeks before surgery.
A written informative consent was obtained from all pa-
tients participating in the study. The clinical research ethics
committee of Fakhry and AlRajhi Hospitals approved the
study and the related patients’ consent. On the day of surgery,
all patients received preoperative intravenous Methylene blue
(tetra-methylthionine chloride) infusion in 500 ml of 5% dex-
trose in a dose of 7.5 mg/kg body. The infusion was started
20 min before incision, and completed before exposure of the
parathyroid gland. The anesthesiologist was alerted to the phe-
nomenon of pseudocyanosis resulting from MB and the possi-
bility of pseudohypoxia and encouraged to depend on pulse-
oximetry.
In superior parathyroid adenomas, a 20 mm transverse inci-
sion was made in a skin crease directly over the localized para-
thyroid gland, along the medial border of the sternomastoid
muscle. The sternomastoid muscle was mobilized laterally
and the strap muscles medially to reveal the lateral margin
of the thyroid gland. In inferior parathyroid adenomas, inci-intraoperative tools used to localize and identify parathyroid
ative time (in min) are mentioned (F: female, M: male; RI: right
ethylene blue).
US CT MRI Tc scan MB Time (min)
+ve +ve – – +ve 34
ve +ve – +ve +ve 35
+ve – – +ve +ve 27
+ve – +ve – +ve 25
+ve +ve – – +ve 24
+ve +ve – – +ve 24
ve – +ve +ve +ve 21
ve ve +ve +ve +ve 22
+ve +ve +ve – +ve 21
tive detection; (–) test not done.
Figure 2 (a and b) Contrast enhanced coronal and axial CT
showing a right inferior parathyroid adenoma (PTA, white
arrows) lying above the bracheocephalic artery below the right
hypoplastic thyroid lobe (th); (d) Technetium-99m sestamibi
parathyroid imaging showing the PTA (black arrow); (e) preop-
erative view of the patient showing the marking of the incision; (e–
g) intraoperative endoscopic views showing the blue coloration of
the PTA which is lying lateral to the trachea (tr) below the right
lobe of the thyroid gland with attached thymus gland, left lobe of
the thyroid (th); (h) postoperative view of the excised PTA with
attached fat (f), and thymus gland.
Figure 1 (a) Coronal T2 weighted MRI showing hyperintense
signal of left superior parathyroid adenoma (PTA, white arrows)
and a nearby cervical lymph node (yellow arrow); th., thyroid
gland; (B) axial T2 weighted MRI showing the hyperintense PTA
(white arrows); (c and d) longitudinal and transverse cervical
ultrasound showing the PTA (red arrows); (e) preoperative view of
the patient showing the marking of the incision; (f and g)
intraoperative endoscopic views showing the blue coloration of the
PTA which is lying posterolateral to the thyroid gland (th) and
anteromedial to the common carotid artery (cc); (h) postoperative
view of the excised PTA and nearby lymph node (L.N.).
Minimally invasive, endoscopic assisted, parathyroidectomy (MIEAP) 27sion was made 3 cm above the suprasternal notch and the strap
muscles were separated in the midline. The 0 endoscope was
used to help in dissection and identiﬁcation of the blue-stained
parathyroid adenoma (after methelyene blue injection).
Complete hemostasis is insured, then wound is closed by
subcuticular suturing, with no drains used. Immediate postop-
erative parathyroid hormone assay was requested. The speci-
men was sent for histopathology. All patients wereconsidered for discharge the following morning. Calcium tab-
lets were prescribed to be taken when needed and patients were
given instructions on how to identify the symptoms of hypocal-
cemia. All patients were seen after 1, 3, 6 and 9 months postop-
eratively. The duration of operation (skin-to-skin time) was
recorded, along with the length of hospital stay, complications
and hormonal conversion rates.
28 M.H. Thabet et al.2.1. Statistical analysis
Descriptive statistics are presented as means, numbers and
percentages.3. Results
Nine patients with PHPT due to single-gland parathyroid ade-
nomas constitute the main framework of this study. They were
seven females and two males, aging 42–53 years (mean = 45.3).
US was done for nine patients with a positive detection in six
patients (66.7%) and negative detection in three patients
(33.3%), CT was requested for six patients with 5 positive
detections (83.3%), while the positive detections for MRI and
sestamibi scans were (100%) in four patients (for each tool).
Preoperative imaging of all patients succeeded to localize
the parathyroid adenoma (100%) using two modalities at least.
Right inferior parathyroid adenoma (RI) (Fig. 2) was
diagnosed in four patients (44.4%). Left superior parathyroid
adenoma (LS), (Fig. 1) was diagnosed in three patients
(33.3%), while the right superior (RS) gland adenoma was
diagnosed in one patient (11.1%), the same value (11.1%)
was recorded with left inferior (Li) adenoma.
All parathyroid adenomas were positively identiﬁed intra-
operatively and stained by MB in all patients with no staining
of the surrounding tissues e.g. thyroid gland, lymph nodes, and
thymus gland (100% accuracy and 100% speciﬁcity). Skin-to-
skin time ranged between 21 and 35 min (mean = 25.3). No
postoperative complications, local or systemic, were detected.
There were no postoperative vocal cord paralysis, or voice
changes as conﬁrmed by videolaryngoscopy, also no allergic
or toxic reactions to MB were recorded. Two females com-
plained of pain at the infusion site, that resolved by decreasing
the rate of infusion. All specimens were proved pathologically
to be parathyroid adenomas, ranging in size between 12 and
23 mm in maximum length (mean 17.1 mm). Hypercalcemia
and parathyroid hormone were corrected in all patients and
followed up for a minimum period of 9 months.
4. Discussion
For many years bilateral neck exploration with identiﬁcation
of four glands remained the gold standard in parathyroid sur-
gery, and routine preoperative imaging for initial surgery was
considered unnecessary and not cost effective.1,2 Time has
changed, and undoubtedly it is the progress of imaging studies
that has modiﬁed the surgical management of patients with
hyperparathyroidism and helped the development of new sur-
gical techniques.10
Recently, minimal-access parathyroidectomy is the current
method of choice for 92% of members of the international
association of endocrine surgeons.1,15,16 The concept of mini-
mally invasive techniques is based on the fact that 85% of pa-
tients will have single-gland disease. The common thread of
new minimally invasive techniques is that the approach is tar-
geted on one speciﬁc parathyroid gland. In most cases the
exploration of other glands is not performed.8,10 The morbid-
ity associated with a standard four-gland parathyroid explora-
tion could be minimized with a less invasive procedure while
maintaining the same level of success at curing the disease.17As the success of limited approaches largely depends on accu-
rate preoperative localization, the surgeon is therefore highly
dependent upon the quality of preoperative localization to
make a judicious choice for a focused approach. Today, the
development and the reported efﬁcacy of noninvasive tech-
niques have tempted many endocrinologists and many sur-
geons to order some of these new noninvasive techniques on
patients undergoing ﬁrst-time parathyroidectomy.10 Most
institutions use preoperative imaging tools either a single agent
or more commonly in combination.10,18–20
In this work, US was requested for the nine patients with
positive detection in six (66.7%) of them. US is used as the
ﬁrst-line of parathyroid imaging for many reasons. It is easily
and quickly performed, and well-tolerated by the patient. It
does not require administration of contrast medium and does
not emit radiation. It provides good anatomic information
about masses in the neck, and when performed by expert radi-
ologist, 95% of adenomas can be identiﬁed. In addition it is
the least expensive preoperative localization technique. The
sensitivity of US is operator, material and size dependent.
The limit of detection is approximately 5 mm.18 US has been
shown to have sensitivity and speciﬁcity of 70–85% and 90–
95%, respectively.19
CT was ordered for six patients, with positive detection in
ﬁve (83.3%) of them. It complements US in four patients and
failed to detect the gland in one patient. CT imaging of
parathyroid glands is relatively expensive, exposes the patient
to radiation and requires the administration of contrast med-
ium. It has a high rate of false-positive results, up to 50%.10
CT had been shown to have sensitivity of 67%.21 MRI and
Technetium (Tc) scanning were the least tools used in this work,
only in four patients, for each one, with positive detection in all
of them (100%).MRI provides excellent anatomic details and is
slightly more sensitive than CT. It does not require intravenous
contrast. Nevertheless, MRI is expensive and patient compli-
ance is sometimes limited by claustrophobia. Parathyroid ade-
noma typically has low signal intensity in T1-weighted
imaging and high signal intensity in T2-weighted imaging.21
Sensitivity rates may reach up to 88%.22 Henry et al. 20017 sta-
ted that MRI is usually reserved as a second line test for local-
ization in reoperative parathyroid surgery when US and
sestamibi scans have failed to identify an abnormal parathyroid
gland which is probably located in the mediastinum.
Coakley et al. ﬁrst reported on the use of Technetium-99m
methoxyisobutyl isonitrile (sestamibi) for parathyroid imag-
ing.23 Sestamibi tends to be concentrated in parathyroid ade-
nomas, but the exact mechanism remains debatable. High
mitochondrial activity is considered to be the major compo-
nent of sestamibi uptake by human parathyroid tissue in pa-
tients with primary hyperparathyroidism.1 The reported
sensitivity is up to 90%.24,25 Wide differences in reported sen-
sitivity exists.26
Authors in this work used MB in the preoperative period
aiming for staining of the abnormal glands and hence intraop-
erative rapid and easy identiﬁcation. MB is a cationic thiazine
dye with a variety of uses including treatment of drug-induced
methemoglobinemia, septic shock, treatment and prevention
of ifosfamide-induced encephalopathy.27 In vitro experiments
also show that intravenous doses of MB inhibit monoamine
oxidase28 and may have direct hippocampal neuronal toxicity
in rats.29 MB is primarily excreted in the urine after reduction
by glucose-6 phosphate dehydrogenase (G6PD).30
Minimally invasive, endoscopic assisted, parathyroidectomy (MIEAP) 29Since its description by Dudley in 1971,11 MB is used in
some head and neck centers for parathyroid surgery due to
the dye’s ability to preferentially stain the parathyroid glands.
This enables greater surgical visualization and consequently
easier resection.13,31,32 A dose up to 7.5 mg/kg is administered
during the hour before surgery, as this is believed to provide
optimal gland staining.8,9 Recent works had noted the devel-
opment of transient neurologic side effects only in those pa-
tients who had been taking a drug that causes an increase in
central serotonin transmission.28,33,34 Ramsay et al., 2007
found MB to act as a potent competitive inhibitor of mono-
amine oxidase A (MAO-A), the enzyme which is principally
responsible for the inactivation of certain monoaminergic neu-
rotransmitters, such as serotonin and norepinephrine by bind-
ing in its active site i.e. MB effectively functions as a MAOI.28
MAOIs are known to precipitate the development of serotonin
toxicity, a rapidly worsening drug–drug interaction involving
the accumulation of extremely high levels of serotonin, when
coadministered with drugs that increase serotonin neurotrans-
mission. Therefore, the combination of MB with a serotoner-
gic drug results in a high risk of precipitating serotonin
toxicity.33,35,36 Also Liker et al., 2008 observed that preopera-
tive intravenous MB markedly decreased the anesthetic
requirements and prolonged the time to awakening in patients
undergoing parathyroid-ectomy.37
In this work, all parathyroid adenomas were positively
stained with MB, which was shown to be a useful diagnostic
tool for patients of parathyroid diseases. The blue staining en-
sures easy visualization and no normal parathyroid gland tis-
sue was stained with MB, in our study, which indicates that
MB administration can help surgeons to preserve normal para-
thyroid glands more easily. Until recently, it remains uneluci-
dated why abnormal parathyroid glands are selectively
stained with MB; however it was hypothesized by Takei et
al., 1999 that both blood supply and retention are increased
in the abnormal parathyroid glands compared to normal para-
thyroid glands or other tissues in the neck.20 Therefore MB
would be easily absorbed into the abnormal parathyroid gland
where it remains longer. In a study by Gordon et al., 1975 it
was found that the staining afﬁnity for the dye was directly re-
lated to the size of the gland. 87% of enlarged glands were
stained, whereas only 25% of normal-sized glands were
stained.38 When these characteristics were correlated with the
histologic diagnosis, 100% of adenomas stained, 85% of
hyperplastic glands stained and only 27% of normal glands
stained. Also, Dudley considered that the intensity of staining
with MB may be related to the number of oxyphil cells present
in the gland such that the higher the number of oxyphils, the
deeper the stain.11,39
In our series, no complications associated with MB were re-
corded, either during early few hours or late postoperative fol-
low up periods. This can be explained by the proper
preoperative preparation and avoidance of those drugs that re-
act and augment the toxic effects of MB.
In conclusion, patients with PHPT due to parathyroid ade-
nomas could be managed by MIEAP in an easy and safe sur-
gical technique and short operative time through a small and
esthetic incision. These results are gained after proper preoper-
ative preparation, imaging localization and intraoperative MB
identiﬁcation. Also, this technique shows less postoperative
hypocalcemia and less postoperative scarring in the neck,
allowing for safer reoperation if needed.40–42References
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